Teva Pharmaceutical Industries Ltd (ADR)  

(Public, NYSE:TEVA)   Watch this stock  
Find more results for teva
49.91
+0.30 (0.60%)
Apr 16 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 49.90 - 50.52
52 week 36.26 - 54.70
Open 50.04
Vol / Avg. 6.62M/7.02M
Mkt cap 47.40B
P/E 33.44
Div/yield 0.34/2.55
EPS 1.49
Shares 949.73M
Beta 0.59
Inst. own 50%
May 1, 2014
Q1 2014 Teva Pharmaceutical Industries Ltd Earnings Conference Call - 8:00AM EDT - Add to calendar
May 1, 2014
Q1 2014 Teva Pharmaceutical Industries Ltd Earnings Release - 7:00AM EDT - Add to calendar
Mar 4, 2014
Teva Pharmaceutical Industries Ltd at Cowen Health Care Conference - Webcast
Feb 26, 2014
Teva Pharmaceutical Industries Ltd at Citi Global Healthcare Conference - Webcast
Feb 24, 2014
Teva Pharmaceutical Industries Ltd Annual Shareholder Meeting
Feb 6, 2014
Q4 2013 Teva Pharmaceutical Industries Ltd Earnings Conference Call - Webcast
Feb 6, 2014
Q4 2013 Teva Pharmaceutical Industries Ltd Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin 7.13% 6.37%
Operating margin 10.31% 8.12%
EBITD margin - 27.58%
Return on average assets 3.26% 2.64%
Return on average equity 6.79% 5.60%
Employees 44,945 -
CDP Score - 73 D

Address

5 Basel St., P.O. Box 3190
PETAH TIKVA, 49131
Israel
+972-3-9267267 (Phone)
+972-3-9234050 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha

Description

Teva Pharmaceutical Industries Ltd (Teva) is an Israel-based pharmaceutical and drug company. It develops, produces and markets generic drugs in all treatment categories. The Company has a pharmaceutical business, whose principal products include Copaxone and Azilect. Teva�s active pharmaceutical ingredient (API) business provides vertical integration to Teva�s own pharmaceutical production. The Company�s global operations are conducted from North and Latin America to Europe and Asia. Teva operates a number of subsidiaries in such countries as Canada, Croatia, the Czech Republic, France, Germany, Hungary, Ireland, Israel, Japan, Poland, the Russian Federation, Spain, the Netherlands, the United Kingdom and the United States. In February 2014, the Company's subsidiary, Train Merger Sub, Inc, fully acquired NuPathe Inc.

Officers and directors

Phillip Frost M.D. Chairman of the Board
Age: 76
Bio & Compensation  - Reuters
Erez Vigodman President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Moshe Many MD,PhD Independent Vice Chairman of the Board
Age: 84
Bio & Compensation  - Reuters
Kobi Altman Acting Chief Financial Officer
Age: 45
Bio & Compensation  - Reuters
Eyal Desheh Chief Financial Officer
Age: 61
Bio & Compensation  - Reuters
Carlo De Notaristefani Ph.D. President and Chief Executive Officer, Global Operations
Age: 55
Bio & Compensation  - Reuters
Robert Koremans M.D. President and Chief Executive Officer, Teva Europe Designate
Age: 51
Bio & Compensation  - Reuters
Itzhak Krinsky Chairman, Teva Japan and Teva South Korea, Head - Business Development Asia-Pacific
Age: 60
Bio & Compensation  - Reuters
Allan Oberman President and Chief Executive Officer of Teva Americas Generics
Age: 55
Bio & Compensation  - Reuters
Judith Vardi President and Chief Executive Officer of Teva EMIA and Asia Pacific
Age: 54
Bio & Compensation  - Reuters